Hubei Jumpcan Pharmaceutical Co Ltd (600566) - Net Assets

Latest as of March 2026: CN¥15.01 Billion CNY ≈ $2.20 Billion USD

Based on the latest financial reports, Hubei Jumpcan Pharmaceutical Co Ltd (600566) has net assets worth CN¥15.01 Billion CNY (≈ $2.20 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥17.84 Billion ≈ $2.61 Billion USD) and total liabilities (CN¥2.82 Billion ≈ $412.99 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible equity quality of Hubei Jumpcan Pharmaceutical Co Ltd to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥15.01 Billion
% of Total Assets	84.18%
Annual Growth Rate	19.92%
5-Year Change	60.25%
10-Year Change	296.82%
Growth Volatility	48.72

Hubei Jumpcan Pharmaceutical Co Ltd - Net Assets Trend (1998–2025)

This chart illustrates how Hubei Jumpcan Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. See defensive interval ratio of Hubei Jumpcan Pharmaceutical Co Ltd to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Hubei Jumpcan Pharmaceutical Co Ltd (1998–2025)

The table below shows the annual net assets of Hubei Jumpcan Pharmaceutical Co Ltd from 1998 to 2025. For live valuation and market cap data, see market value of Hubei Jumpcan Pharmaceutical Co Ltd.

Year	Net Assets	Change
2025-12-31	CN¥14.63 Billion ≈ $2.14 Billion	-0.64%
2024-12-31	CN¥14.73 Billion ≈ $2.15 Billion	+10.15%
2023-12-31	CN¥13.37 Billion ≈ $1.96 Billion	+17.76%
2022-12-31	CN¥11.35 Billion ≈ $1.66 Billion	+24.33%
2021-12-31	CN¥9.13 Billion ≈ $1.34 Billion	+17.62%
2020-12-31	CN¥7.76 Billion ≈ $1.14 Billion	+27.17%
2019-12-31	CN¥6.10 Billion ≈ $893.27 Million	+11.85%
2018-12-31	CN¥5.46 Billion ≈ $798.65 Million	+23.99%
2017-12-31	CN¥4.40 Billion ≈ $644.12 Million	+19.37%
2016-12-31	CN¥3.69 Billion ≈ $539.60 Million	+35.93%
2015-12-31	CN¥2.71 Billion ≈ $396.97 Million	+18.26%
2014-12-31	CN¥2.29 Billion ≈ $335.68 Million	+99.06%
2013-12-31	CN¥1.15 Billion ≈ $168.63 Million	+134.80%
2012-12-31	CN¥490.80 Million ≈ $71.82 Million	-6.84%
2011-12-31	CN¥526.82 Million ≈ $77.09 Million	+1.26%
2010-12-31	CN¥520.27 Million ≈ $76.13 Million	+1.45%
2009-12-31	CN¥512.85 Million ≈ $75.05 Million	+1.32%
2008-12-31	CN¥506.18 Million ≈ $74.07 Million	+1.47%
2007-12-31	CN¥498.83 Million ≈ $72.99 Million	+2.68%
2006-12-31	CN¥485.82 Million ≈ $71.09 Million	+1.16%
2005-12-31	CN¥480.25 Million ≈ $70.28 Million	+1.34%
2004-12-31	CN¥473.92 Million ≈ $69.35 Million	+1.60%
2003-12-31	CN¥466.47 Million ≈ $68.26 Million	+1.62%
2002-12-31	CN¥459.05 Million ≈ $67.17 Million	+2.11%
2001-12-31	CN¥449.57 Million ≈ $65.79 Million	+221.10%
2000-12-31	CN¥140.01 Million ≈ $20.49 Million	+11.59%
1999-12-31	CN¥125.46 Million ≈ $18.36 Million	+15.70%
1998-12-31	CN¥108.44 Million ≈ $15.87 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Hubei Jumpcan Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 219795.5% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Retained Earnings	CN¥10.04 Billion	68.75%
Other Components	CN¥4.56 Billion	31.25%
Total Equity	CN¥14.61 Billion	100.00%

Hubei Jumpcan Pharmaceutical Co Ltd Competitors by Market Cap

The table below lists competitors of Hubei Jumpcan Pharmaceutical Co Ltd ranked by their market capitalization.

Company	Market Cap
Helmerich and Payne Inc NYSE:HP	$3.49 Billion
Tianneng Battery Group Co Ltd SHG:688819	$3.50 Billion
CIE Automotive S.A. MC:CIE	$3.50 Billion
ROCKWOOL International A/S CO:ROCK-A	$3.50 Billion
MINISO GRP HLD.ADS/4 F:MIF	$3.49 Billion
Life360, Inc. Common Stock NASDAQ:LIF	$3.49 Billion
Changzhou Fusion New Material Co. Ltd. A SHG:688503	$3.49 Billion
Aperam SA F:7AA	$3.49 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Hubei Jumpcan Pharmaceutical Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 14,701,852,749 to 14,605,549,346, a change of -96,303,403 (-0.7%).
Net income of 1,777,852,640 contributed positively to equity growth.
Dividend payments of 1,928,582,313 reduced retained earnings.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	CN¥1.78 Billion	+12.17%
Dividends Paid	CN¥1.93 Billion	-13.2%
Other Changes	CN¥54.43 Million	+0.37%
Total Change	CN¥-	-0.66%

Book Value vs Market Value Analysis

This analysis compares Hubei Jumpcan Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.63x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 32.98x to 1.63x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
1998-12-31	CN¥0.79	CN¥25.91	x
1999-12-31	CN¥0.91	CN¥25.91	x
2000-12-31	CN¥1.01	CN¥25.91	x
2001-12-31	CN¥3.26	CN¥25.91	x
2002-12-31	CN¥3.32	CN¥25.91	x
2003-12-31	CN¥3.37	CN¥25.91	x
2004-12-31	CN¥3.43	CN¥25.91	x
2005-12-31	CN¥3.47	CN¥25.91	x
2006-12-31	CN¥3.51	CN¥25.91	x
2007-12-31	CN¥3.60	CN¥25.91	x
2008-12-31	CN¥3.65	CN¥25.91	x
2009-12-31	CN¥4.81	CN¥25.91	x
2010-12-31	CN¥3.75	CN¥25.91	x
2011-12-31	CN¥3.81	CN¥25.91	x
2012-12-31	CN¥0.80	CN¥25.91	x
2013-12-31	CN¥1.89	CN¥25.91	x
2014-12-31	CN¥2.96	CN¥25.91	x
2015-12-31	CN¥3.42	CN¥25.91	x
2016-12-31	CN¥4.58	CN¥25.91	x
2017-12-31	CN¥5.43	CN¥25.91	x
2018-12-31	CN¥6.69	CN¥25.91	x
2019-12-31	CN¥7.49	CN¥25.91	x
2020-12-31	CN¥9.30	CN¥25.91	x
2021-12-31	CN¥10.14	CN¥25.91	x
2022-12-31	CN¥12.48	CN¥25.91	x
2023-12-31	CN¥14.57	CN¥25.91	x
2024-12-31	CN¥16.03	CN¥25.91	x
2025-12-31	CN¥15.85	CN¥25.91	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Hubei Jumpcan Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 12.17%
The company shows good efficiency in utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 28.59%
• Asset Turnover: 0.35x
• Equity Multiplier: 1.21x
Recent ROE (12.17%) is below the historical average (14.42%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
1998	9.80%	16.33%	0.35x	1.72x	CN¥-216.00K
1999	13.57%	20.77%	0.42x	1.57x	CN¥4.48 Million
2000	10.39%	14.87%	0.44x	1.60x	CN¥545.98K
2001	3.94%	15.53%	0.20x	1.30x	CN¥-27.26 Million
2002	3.03%	12.95%	0.18x	1.33x	CN¥-31.92 Million
2003	1.59%	6.53%	0.17x	1.40x	CN¥-39.15 Million
2004	1.57%	5.08%	0.21x	1.48x	CN¥-39.87 Million
2005	1.76%	4.79%	0.24x	1.53x	CN¥-39.50 Million
2006	2.01%	4.85%	0.26x	1.62x	CN¥-38.76 Million
2007	2.18%	4.98%	0.27x	1.61x	CN¥-38.91 Million
2008	1.66%	3.93%	0.26x	1.64x	CN¥-42.13 Million
2009	1.51%	3.47%	0.27x	1.63x	CN¥-43.47 Million
2010	1.63%	3.57%	0.27x	1.66x	CN¥-43.46 Million
2011	1.51%	3.29%	0.25x	1.83x	CN¥-44.66 Million
2012	48.54%	12.38%	1.93x	2.03x	CN¥188.70 Million
2013	34.95%	16.45%	1.22x	1.75x	CN¥287.48 Million
2014	22.64%	17.39%	0.89x	1.46x	CN¥289.99 Million
2015	25.73%	18.22%	1.05x	1.34x	CN¥419.77 Million
2016	25.54%	19.97%	0.94x	1.36x	CN¥568.45 Million
2017	27.79%	21.68%	0.85x	1.51x	CN¥783.28 Million
2018	30.93%	23.42%	0.92x	1.43x	CN¥1.14 Billion
2019	26.59%	23.39%	0.80x	1.42x	CN¥1.01 Billion
2020	16.45%	20.72%	0.59x	1.35x	CN¥500.89 Million
2021	18.86%	22.53%	0.63x	1.33x	CN¥807.49 Million
2022	19.15%	24.13%	0.60x	1.32x	CN¥1.04 Billion
2023	21.15%	29.24%	0.53x	1.36x	CN¥1.49 Billion
2024	17.22%	31.58%	0.43x	1.26x	CN¥1.06 Billion
2025	12.17%	28.59%	0.35x	1.21x	CN¥317.30 Million

Industry Comparison

This section compares Hubei Jumpcan Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $4,041,443,343
Average return on equity (ROE) among peers: 10.73%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Hubei Jumpcan Pharmaceutical Co Ltd (600566)	CN¥15.01 Billion	9.80%	0.19x	$3.49 Billion
Shenzhen Neptunus Bioengineering Co Ltd (000078)	$971.04 Million	5.41%	3.98x	$565.97 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153)	$1.33 Billion	6.10%	1.68x	$359.03 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423)	$8.39 Billion	22.09%	0.19x	$4.30 Billion
Livzon Pharmaceutical Group Inc (000513)	$3.01 Billion	11.93%	0.53x	$2.52 Billion
Wedge Industrial Co Ltd (000534)	$1.15 Billion	11.42%	1.59x	$2.41 Billion
Yunnan Baiyao Group Co Ltd (000538)	$1.42 Billion	23.64%	1.01x	$12.64 Billion
Hainan Haiyao Co Ltd (000566)	$445.29 Million	14.73%	0.90x	$715.72 Million
Tus Pharmaceutical Group Co Ltd (000590)	$347.80 Million	3.58%	0.72x	$319.94 Million
Northeast Pharmaceutical Group Co Ltd (000597)	$905.53 Million	2.15%	1.95x	$916.75 Million
Jilin Aodong Pharmaceutical Group Co Ltd (000623)	$22.44 Billion	6.25%	0.15x	$3.00 Billion

About Hubei Jumpcan Pharmaceutical Co Ltd

SHG:600566 China Drug Manufacturers - Specialty & Generic

Market Cap

$3.49 Billion

CN¥23.88 Billion CNY

Market Cap Rank

#4567 Global

#790 in China

Share Price

CN¥25.91

Change (1 day)

-1.30%

52-Week Range

CN¥24.32 - CN¥28.97

All Time High

CN¥44.43